Table 1.
Baseline characteristics n = 166.
| Recipient | |
| Age at OHT | 46.2 (±11.4) |
| Sex (male) | 127 (76.5) |
| BMI in kg/m² | 25.2 (±4.0) |
| Waiting list status | |
| Highly urgent | 146 (88.0) |
| Urgent (until February 2011) | 4 (2.4) |
| Transplantable | 16 (9.6) |
| Diagnosis leading to OHT | |
| DCM | 114 (68.7) |
| HCM | 4 (2.4) |
| RCM | 0 |
| ARVC | 3 (1.8) |
| IHD | 35 (21.1) |
| Other * | 10 (6.0) |
| Previous VAD | 84 (50.6) |
| LVAD | 78 (47.0) |
| RVAD | 1 (0.6) |
| BVAD | 6 (3.6) |
| Concomitant disease | |
| CKD | 115 (69.3) |
| DM | 26 (15.7) |
| Type 1 | 4 (2.4) |
| Type 2 | 22 (13.3) |
| HLP | 64 (38.6) |
| Former smoker | 38 (22.9) |
| Donor | |
| Age at donation | 40.8 (±14.1) |
| Sex (male) | 107 (64.5) |
| BMI in kg/m² | 25.2 (±3.7) |
| Echocardiography | |
| LV hypertrophy | 12 (7.2) |
| Concomitant disease | |
| Hypertension | 22 (13.3) |
| CAD | 2 (1.2) |
| DM | 6 (3.6) |
| Former smoker | 26 (15.7) |
| Alcohol abuse | 16 (9.6) |
| Drug abuse † | 7 (4.2) |
| Cardiopulmonary resuscitation | 20 (12.0) |
| Transplantation | |
| Combined OHT | |
| Heart–kidney | 3 (1.8) |
| Ischemic time in min | 259.9 (±63.3) |
| ICU stay in days | 26.7 (±36.3) |
| Hospital stay in days | 62.3 (±50.7) |
| Inotropic support in days | 8 (5–12) |
| Mechanical ventilation in days | 5 (2–18) |
| GFR at discharge in ml/min | |
| >90 | 67 (40.2) |
| 60–89 | 35 (21.1) |
| 40–59 | 22 (13.3) |
| 30–44 | 19 (11.4) |
| 15–29 | 8 (4.8) |
| RRT | 16 (9.6) |
| Immunosuppression induction | |
| Cyclosporine | 162 (97.2) |
| Tacrolimus | 4 (2.4) |
| Mycophenolate mofetil | 9 (5.4) |
| Methylprednisolone | 166 (100.0) |
| Antithymocyte globulin | 100 (60.2) |
| Other § | 4 (2.4) |
| Immunosuppression at discharge | |
| Cyclosporine | 92 (55.4) |
| Tacrolimus | 71 (42.8) |
| Everolimus | 19 (11.4) |
| Mycophenolate mofetil | 132 (79.5) |
| Methylprednisolone | 164 (98.8) |
| Unknown | 2 (1.2) |
ARVC, arrhythmogene right ventricular cardiomyopathy; BMI, body mass index; BVAD, biventricular assist device; CKD, chronic kidney disease; DCM, dilated cardiomyopathy; DM, diabetes mellitus; GFR, glomerular filtration rate; HCM, hypertrophic cardiomyopathy; HLP, hyperlipidemia; ICU, intensive care unit; IHD, ischemic heart disease; LVAD, left ventricular assist device; OHT, orthotopic heart transplantation; RCM, restrictive cardiomyopathy; RRT, renal replacement therapy; RVAD, right ventricular assist device; VAD, ventricular assist device; * others: transposition of the great arteries, noncompaction cardiomyopathy, peripartum cardiomyopathy; † drug abuse: unknown, cannabis, cocaine, polytoxicomania; § others: basiliximab, plasmapheresis, rituximab.